Clinicopathological characteristics and prognosis of uterine serous carcinoma: A SEER program analysis of 1016 cases

2021 ◽  
Author(s):  
Ying Han ◽  
Chongdong Liu
Keyword(s):  
Program Analysis ◽  
Clinicopathological Characteristics ◽  
Seer Program ◽  
Serous Carcinoma ◽  
Uterine Serous Carcinoma

scholarly journals Uterine serous carcinoma: key advances and novel treatment approaches

2021 ◽  
pp. ijgc-2021-002753
Author(s):  
J Stuart Ferriss ◽  
Britt K Erickson ◽  
Ie-Ming Shih ◽  
Amanda N Fader
Keyword(s):  
Endometrial Cancer ◽  
Black Women ◽  
Treatment Options ◽  
Molecular Genetic ◽  
Serous Carcinoma ◽  
Cancer Syndrome ◽  
Her2 Positive ◽  
Incidence And Mortality ◽  
History Of ◽  
Uterine Serous Carcinoma

The incidence and mortality rates from endometrial cancer continue to increase worldwide, while rates in most other cancers have either plateaued or declined considerably. Uterine serous carcinoma represents a fraction of all endometrial malignancies each year, yet this histology is responsible for nearly 40% of all endometrial cancer-related deaths. These deaths disproportionately affect black women, who have higher rates of advanced disease at diagnosis. Molecular genetic analyses reveal major alterations including TP53 mutation, PIK3CA mutation/amplification, ERBB2 amplification, CCNE1 amplification, FBXW7 mutation/deletion, PPP2R1A mutation, and somatic mutations involving homologous recombination genes. Clinical risk factors for uterine serous carcinoma include advancing age, a history of breast cancer, tamoxifen usage, and the hereditary breast–ovarian cancer syndrome. Surgery remains the cornerstone of treatment. Recent advances in our understanding of uterine serous carcinoma molecular drivers have led to development of targeted therapeutics that promise improved outcomes for patients. Overexpression or amplification of HER2 in uterine serous carcinoma carries a poor prognosis; yet this actionable target has led to the incorporation of several anti-HER2 therapies, including trastuzumab which, when added to conventional chemotherapy, is associated with improved survival for women with advanced and recurrent HER2-positive disease. The combination of pembrolizumab and lenvatinib is also a promising targeted treatment strategy for women with uterine serous carcinoma, with a recent phase II study suggesting a 50% response rate in women with recurrent disease. Several trials examining additional targeted agents are ongoing. Despite years of stalled progress, meaningful, tailored treatment options are emerging for patients with this uncommon and biologically aggressive endometrial cancer subtype.

Is platinum-free interval relevant in recurrent uterine serous carcinoma?

2020 ◽  
Vol 159 ◽  
pp. 205-206
Author(s):  
R.N. Beavers ◽  
B. Fellman ◽  
M. Eyada ◽  
A.H. Klopp ◽  
N.D. Fleming ◽  
...  
Keyword(s):  
Serous Carcinoma ◽  
Free Interval ◽  
Uterine Serous Carcinoma

Early stage uterine serous carcinoma: Management updates and genomic advances

2013 ◽  
Vol 129 (1) ◽  
pp. 244-250 ◽  
Author(s):  
Amanda Nickles Fader ◽  
Alessandro D. Santin ◽  
Paola A. Gehrig
Keyword(s):  
Early Stage ◽  
Serous Carcinoma ◽  
Uterine Serous Carcinoma
Sign in / Sign up

Export Citation Format

Share Document